National Institute for Health and Care Excellence (NICE)

What National Institute for Health and Care Excellence (NICE) does

The National Institute for Health and Care Excellence (NICE) is a UK non-departmental public body established in 1999 that produces evidence-based guidance, quality standards, and health technology assessments for the NHS and wider health and care system. Its core products include clinical, public health, and social care guidelines; technology appraisals evaluating the clinical and cost-effectiveness of new medicines, medical devices, diagnostics, and digital health technologies; a library of 200+ quality standards; and authoritative knowledge resources such as the British National Formulary (BNF) and Clinical Knowledge Summaries (CKS) covering 370+ topics. NICE also produces Patient Decision Aids to support shared decision-making between clinicians and patients.

Underlying NICE's work is a health technology assessment methodology built on independent committees that include health and care professionals, patients, carers, and academic experts. The organisation operates supporting programmes such as Managed Access Schemes, the Innovative Licensing and Access Pathway (ILAP), the NICE Advice Service for life-sciences companies, the META Tool for medical technology developers, UK PharmaScan horizon scanning, and the NICE Syndication API, which distributes guidance content through commercial partners such as Elsevier's ClinicalKey. NICE International extends the methodology through advisory engagements with foreign governments, including a renewed 2026-2028 partnership with Taiwan's NHIA and CDE.

NICE does not generate commercial revenue. It is funded by the UK government via the Department of Health and Social Care and operates under statutory authority that requires NHS England to consider its guidance in commissioning decisions. Complementary income is generated through international content licensing, life-sciences advisory services, and educational programmes (including a co-developed LSE Executive MSc in Healthcare Decision-Making). Its customer base spans NHS commissioning bodies, pharmaceutical and life-sciences companies, healthcare practitioners, social care providers, and patients.

Name

National Institute for Health and Care Excellence (NICE)

Legal name

National Institute for Health and Care Excellence

Website

https://nice.org.uk

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The UK National Institute for Health and Care Excellence (NICE) is a government-funded non-departmental public body that produces evidence-based clinical guidelines, health technology assessments, and quality standards for the NHS and social care system.

Ownership category

akta.pro rank

Product category

Health Technology Assessment Services

NAICS

Health Care and Social Assistance (62), Research and Development in the Social Sciences and Humanities (54172)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM) (HLACAHAC), Health Data, Vital Statistics & Population Health Informatics (BPAIAJAM)

Keywords

• Health technology assessment
• Clinical guidelines
• Medical technology appraisal
• Quality standards
• Evidence-based guidance

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Distribution channels5 records

Marketing channels7 records

Core offering

NICE produces independent, evidence-based guidance, standards, and advice for the NHS and wider health and care system in England. Its core programmes include clinical and social care guidelines, technology appraisals for medicines and health technologies, HealthTech guidance covering digital technologies and AI, and over 200 quality standards. Supporting offerings include the British National Formulary, Clinical Knowledge Summaries, Patient Decision Aids, the NICE Advice Service for life sciences companies, the Innovative Licensing and Access Pathway (ILAP), and the NICE Syndication API for content distribution.

Product overview

NICE is the UK's independent health technology assessment body that produces evidence-based guidance, standards, and advice for the NHS and social care system. The core offering consists of multiple guidance programmes: NICE Guidelines (clinical, public health, and social care), Technology Appraisals (assessing new medicines and health technologies), HealthTech Guidance (evaluating digital technologies, diagnostics, and medical devices including AI), and Quality Standards (measuring care quality across 200+ priority areas). These are supported by foundational knowledge resources including the British National Formulary (BNF), Clinical Knowledge Summaries (CKS) with 370+ clinical topics, and Patient Decision Aids for shared decision making. NICE offers commercial services for the life sciences industry including the NICE Advice Service for product development support, the Innovative Licensing and Access Pathway (ILAP) for accelerated market access, the NICE Syndication API for content distribution, and the META Tool for medical technology developers. International advisory services are provided through NICE International. The organisation operates managed access schemes and patient access pricing agreements to enable faster adoption of innovative treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• NICE Guidelines Evidence-based clinical, public health, social care, and medicines practice guidelines developed by independent committees for the NHS and wider health and care system. Used by healthcare practitioners, commissioners, and patients to support evidence-based decision making.
• Technology Appraisals Assessments of clinical and cost effectiveness of new health technologies including medicines, medical devices, and diagnostics for NHS funding recommendations. Produced for NHS England and life sciences companies seeking market access.
• HealthTech Guidance Evaluates digital technologies, diagnostics, and medical devices including AI systems. Includes guidance on early-use, established-use, and existing-use healthtech products. Targeted at NHS commissioners and healthtech developers.
• Quality Standards and Indicators Library of over 200 quality standards and indicators designed to define and measure quality in health, public health, and social care. Used by NHS organisations, commissioners, and quality improvement teams.
• British National Formulary (BNF) Authoritative information on prescription drugs, dispensing, and administration for healthcare professionals in the UK. Published jointly by NICE and the British Medical Association.
• Clinical Knowledge Summaries (CKS) Quick-reference summaries of evidence-based clinical knowledge covering over 370 topics for primary care professionals including GPs, nurses, and pharmacists.
• Patient Decision Aids Evidence-based tools helping patients understand treatment options, likely outcomes, benefits, harms, and uncertainties for shared decision making. Used by patients, families, carers, and healthcare professionals.
• NICE Syndication API Application programming interface providing access to NICE guidance content for embedding in third-party platforms and services. Delivered in XML, JSON, and HTML formats. Used by Elsevier's ClinicalKey and other enterprise integrators globally.
• NICE Advice Service Commercial advisory service helping life sciences companies optimize product development, evidence generation, and market access strategies for NHS reimbursement.
• Innovative Licensing and Access Pathway (ILAP) Collaborative pathway working with medicine developers early to accelerate patient access to innovative treatments through coordinated regulatory and reimbursement engagement.
• NICE International Advisory service for international health organisations, ministries, and government agencies to improve evidence-based decision making. Supports HTA framework development and capacity building globally.
• NHS Knowledge and Library Hub Provided in partnership between NHS England and NICE, the NHS Knowledge and Library Hub provides healthcare staff access to journals, databases, and evidence-based resources including BMJ Best Practice and Cochrane Library through NHS OpenAthens authentication.

Quantifiable outcome

• Hybrid closed loop technology uptake increased from 36% to 73% for children and young people with type 1 diabetes
• +3 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability10 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Taiwan National Health Insurance Administration (NHIA)coreStrategic or Co-development Partner · 11 May 2026Renewed two-year partnership agreement (2026-2028) extending collaboration on health technology assessment frameworks, digital transformation in cancer care, and HTA talent development. Taiwan has implemented a provisional payment system inspired by the UK's Cancer Drugs Fund.
• Taiwan Center for Drug Evaluation (CDE)coreStrategic or Co-development Partner · 11 May 2026Joint collaboration with NHIA on HTA frameworks, sharing digital governance experiences for cancer care, and establishing real-world evaluation systems for treatment outcomes. Partnership first signed in 2023.
• Medicines and Healthcare products Regulatory Agency (MHRA)coreStrategic or Co-development Partner · 19 March 2026Launched aligned pathway for simultaneous licensing and reimbursement decisions on new marketing applications. First guidance due June 2026. Initiative part of NHS 10-Year Plan and Life Sciences Sector Plan, potentially making new therapies available 3-6 months earlier.
• NHS EnglandcoreOthers · 21 December 2025Prof Jonathan Benger appointed as new NICE CEO following roles at NHS Digital and NHS England. Appointment amid ongoing reforms to enhance NHS technology adoption and medicine access.
• NHS EnglandcoreStrategic or Co-development PartnerOngoing collaboration on health technology adoption. NHS England set target to use robotic assistance in nine out of ten keyhole surgeries by 2035. NICE has conditionally recommended 11 robot-assisted surgical systems for specified indications.
• Department of Health and Social CarecoreStrategic or Co-development PartnerJoint involvement in 10 Year Health Plan and Life Sciences Sector Plan. Collaborates on National HealthTech Access Programme to evaluate high-impact healthtech with national NHS funding.
• UK Government Joint Taskforce on Life SciencescoreStrategic or Co-development PartnerJoint Taskforce launched to promote innovation and accelerate progress in life sciences sector as part of 10 Year Health Plan. Report expected to ministers and industry leaders by September 2026.
• Global Justice NowminorOthersCampaign group that has threatened UK government with judicial review over UK-US drug pricing deal, arguing changes undermine NICE's independence.
• Just TreatmentminorOthersCampaign group joining Global Justice Now in threatening legal action over secondary legislation granting health secretaries power to override NICE on drug pricing decisions.
• Rare Disease ConsortiumcoreStrategic or Co-development PartnerPartnership comprising patients, academics, industry and healthcare partners working with MHRA on proposed Rare Disease Therapies Regulatory Framework that could enable earlier licensing of treatments for rare diseases.
• Academy of Medical Royal CollegesminorStrategic or Co-development PartnerPartner in shared decision making collaborative working with over 40 organisations to support wider health and care system in putting shared decision making into routine practice.
• Health Education EnglandminorStrategic or Co-development PartnerPartner in shared decision making collaborative supporting health and care professionals in developing skills for shared decision making conversations.
• General Medical CouncilminorStrategic or Co-development PartnerPartner in shared decision making collaborative helping ensure medical professionals understand the importance of balancing professional judgment with patient needs and wishes.
• Healthwatch EnglandminorStrategic or Co-development PartnerPartner in shared decision making collaborative representing patients and public perspective in health and care decision making.
• Keele UniversityminorStrategic or Co-development PartnerCollaborated with NICE to develop shared decision making learning package for healthcare professionals to build skills and knowledge for conversations with patients.
• London School of Economics and Political Science (LSE)minorStrategic or Co-development PartnerCo-developed Executive MSc Healthcare Decision-Making master's degree with NICE for professionals seeking advanced training in health technology assessment.
• NHS England (Knowledge and Library Services)coreStrategic or Co-development PartnerProvided in partnership between NHS England and NICE, the NHS Knowledge and Library Hub provides healthcare staff access to journals, databases, and evidence-based resources.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Institute for Quality and Efficiency in Health Care (IQWiG): Germany's HTA body that evaluates clinical benefit of pharmaceuticals for the G-BA. Closely comparable to NICE in methodology, function, and statutory role within a national reimbursement framework, though operates within Germany's social insurance system rather than a single-payer NHS.
• Pharmaceutical Benefits Advisory Committee (PBAC): Australia's independent expert body that recommends which medicines should be subsidized under the Pharmaceutical Benefits Scheme. Directly comparable as a national HTA body whose decisions determine public reimbursement of medicines.
• Haute Autorité de Santé (HAS): France's independent health authority producing HTA, clinical guidelines, and quality standards. Directly comparable to NICE in scope (medicines assessment, guidance, quality indicators) and statutory independence within the French health system.
• Zorginstituut Nederland (ZIN): Netherlands' HTA body advising on the basic health insurance package. Comparable to NICE in evaluating clinical effectiveness and cost-effectiveness for national reimbursement decisions, often cited as a peer in European HTA methodology.
• Canadian Agency for Drugs and Technologies in Health (CADTH): Canada's national HTA agency providing reimbursement recommendations to federal, provincial, and territorial drug plans. Comparable to NICE in producing health technology assessments and clinical guidance, with similar mandate to inform public reimbursement decisions.
• Institute for Clinical and Economic Review (ICER): US-based independent HTA body producing cost-effectiveness analyses for pharmaceuticals and medical devices. Directly comparable to NICE as a non-government HTA organization that influences US payer decisions, though lacks NICE's statutory authority.

Regional players

• Scottish Intercollegiate Guidelines Network (SIGN): Produces clinical guidelines for Scotland, paralleling NICE's clinical guideline function but serving NHS Scotland. Comparable as a UK guideline producer with overlapping methodology and scope.
• Scottish Medicines Consortium (SMC): Scotland's HTA body that advises NHS Scotland on new medicines. Comparable to NICE in function but operates in a different UK devolved jurisdiction, providing an alternative pathway for manufacturers.

Broad incumbents

• Agency for Healthcare Research and Quality (AHRQ): US federal agency producing evidence reports, clinical guidelines, and quality measures. Comparable in quality standards and evidence synthesis function, though broader in scope and lacks NICE's reimbursement decision authority.

Others

• European Network for Health Technology Assessment (EUnetHTA): EU-wide HTA collaboration including joint clinical assessments under the EU HTA Regulation. Comparable as a coordinating HTA body, and its 2025 implementation creates both collaboration and competitive dynamics for NICE internationally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/NICEcomms
• YouTubeyoutube.com/user/NICEmedia
• Facebooken-gb.facebook.com/NationalInstituteforHealthandCareExcellence
• LinkedInlinkedin.com/company/national-institute-for-health-and-clinical-excellence

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Institute for Health and Care Excellence (NICE)